Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction

BACKGROUND: Angiotensin receptor neprilysin inhibitor (ARNi) therapy improves clinical outcomes in patients with heart failure and reduced left ventricular ejection fraction. However, ARNi therapy uptake remains modest, potentially in part due to perceived cost considerations of early transition fro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CJC Open
Main Authors: Grant, Andrew D.M., Chew, Derek S., Howlett, Jonathan G., Miller, Robert J.H.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710928/
https://ncbi.nlm.nih.gov/pubmed/33305203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cjco.2020.05.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados